About OXB
OXB is a company based in Oxford (United Kingdom) founded in 1995 by Neill Mackenzie. It operates as a Managed Services and Professional Services. The company has 861 employees as of December 31, 2024. OXB has completed 4 acquisitions, including ABL, ABL Europe and Homology Medicines. OXB offers products and services including LentiVector™ Platform, inAAVate™ Platform, and CDMO Services. OXB operates in a competitive market with competitors including Orgenesis, Ori Biotech, MaSTherCell, Cognate Bioservices and Cell-Easy, among others.
- Headquarter Oxford, United Kingdom
- Employees 861 as on 31 Dec, 2024
- Founders Neill Mackenzie
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Oxford Biomedica Plc
-
Annual Revenue
$161.38 M (USD)43.84as on Dec 31, 2024
-
Net Profit
-$54.11 M (USD)72.58as on Dec 31, 2024
-
EBITDA
-$29.18 M (USD)61.28as on Dec 31, 2024
-
Latest Funding Round
$81.34 M (USD), Post-IPO
Aug 15, 2025
-
Investors
Briarwood Chase Management
& 1 more
-
Employee Count
861
as on Dec 31, 2024
-
Investments & Acquisitions
ABL
& 3 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of OXB
OXB is a publicly listed company on the LSE with ticker symbol OXB in UK, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of OXB
OXB offers a comprehensive portfolio of products and services, including LentiVector™ Platform, inAAVate™ Platform, and CDMO Services.
Innovative lentiviral gene delivery technology is commercially approved.
Proven AAV vector development ensures high-quality clinical products.
End-to-end viral vector manufacturing supports cell therapy clients.
People of OXB
Unlock access to complete
Unlock access to complete
Software Development Team
37 people
Leadership Team
27 people
Product Management Team
21 people
Senior Team
20 people
Scientist Team
7 people
Legal and Compliance
6 people
Sales and Marketing
6 people
Operations Team
6 people
Unlock access to complete
Funding Insights of OXB
Investors in OXB
OXB has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Briarwood Chase Management and Novo Holdings.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private equity and venture capital fund focused on the healthcare sector
|
Locked | Locked | Locked | |
|
Briarwood Chase Management is focused on long-term global investments.
|
Locked | Locked | Locked |
Investor details for OXB
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by OXB
OXB has strategically engaged in corporate development activities, having acquired 4 companies. Notable acquisitions include ABL, ABL Europe and Homology Medicines.
Investment portfolio details for OXB
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Developer of gene therapies for rare genetic diseases
|
Locked | Locked | 2015 | Locked | |
|
Biotechnology products are developed to enhance immune responses against diseases.
|
Locked | Locked | 2004 | Locked | |
|
Contract research and manufacturing for biologics and vaccines are provided.
|
Locked | Locked | 1961 | Locked |
Complete acquisition details for OXB
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - OXB
Detailed financials for OXB
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Oxb Comparisons
Peer comparison for OXB
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of OXB
OXB operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Orgenesis, Ori Biotech, MaSTherCell, Cognate Bioservices and Cell-Easy, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Cell and gene therapies for multiple disorders are developed.
|
|
| Locked | Locked | Locked |
Software development services are provided for the biopharma sector.
|
|
| Locked | Locked | Locked |
Services for cell therapy development and manufacturing are provided.
|
|
| Locked | Locked | Locked |
Development and manufacturing services for cell-based therapies are provided.
|
|
| Locked | Locked | Locked |
Stem cell-based therapy services for research solutions are provided.
|
|
| Locked | Locked | Locked |
A biotechnology company focused on anti-aging therapeutics development.
|
Detailed competitors of OXB
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Oxb
Complete news archive for OXB
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about OXB
OXB was founded in 1995 and raised its 1st funding round 24 years after it was founded.
OXB is headquartered in Oxford, United Kingdom. It is registered at Oxford, Oxfordshire, United Kingdom.
Tim Kelly is the current CEO of OXB.
As of Dec 31, 2024, the latest employee count at OXB is 861.
Annual revenue of OXB is $161.38M as on Dec 31, 2024.
OXB is established as a global leader in cell and gene therapy contract development and manufacturing (CDMO), with over 30 years of expertise in viral vectors. Services are provided to innovative pharmaceutical and biotechnology companies, covering lentivirus, AAV, adenovirus, and other vector types. End-to-end capabilities are offered, from early-stage development to commercialization, supported by robust quality systems and regulatory knowledge. Operations span multiple sectors within healthcare, focusing on enabling life-changing therapies for patients worldwide through advanced manufacturing and development solutions.
OXB's top competitors include Ori Biotech, MaSTherCell and Genflow Biosciences.
OXB offers LentiVector™ Platform, inAAVate™ Platform, and CDMO Services.
Yes, OXB is publicly traded on LSE under the ticker symbol OXB.
OXB has made 4 acquisitions, including ABL, ABL Europe, and Homology Medicines.
OXB has 2 investors. Key investors include Briarwood Chase Management, and Novo Holdings.
The ticker symbol of OXB is OXB on LSE.